Insider Selling: Five Prime Therapeutics Inc (NASDAQ:FPRX) Director Sells 32,090 Shares of Stock

Share on StockTwits

Five Prime Therapeutics Inc (NASDAQ:FPRX) Director Franklin M. Berger sold 32,090 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $3.92, for a total transaction of $125,792.80. Following the transaction, the director now owns 52,890 shares of the company’s stock, valued at approximately $207,328.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Five Prime Therapeutics stock remained flat at $$4.00 during trading on Wednesday. 327,158 shares of the stock traded hands, compared to its average volume of 379,916. The company has a 50 day simple moving average of $3.85 and a two-hundred day simple moving average of $5.39. The firm has a market capitalization of $142.66 million, a PE ratio of -0.97 and a beta of 2.39. The company has a debt-to-equity ratio of 0.26, a quick ratio of 6.93 and a current ratio of 6.93. Five Prime Therapeutics Inc has a 12-month low of $3.18 and a 12-month high of $13.84.

Five Prime Therapeutics (NASDAQ:FPRX) last released its earnings results on Wednesday, November 6th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by ($0.08). The firm had revenue of $2.98 million during the quarter, compared to the consensus estimate of $4.33 million. Five Prime Therapeutics had a negative return on equity of 65.39% and a negative net margin of 921.30%. Analysts forecast that Five Prime Therapeutics Inc will post -4.01 earnings per share for the current year.

Several equities analysts have commented on FPRX shares. Cowen reiterated a “buy” rating on shares of Five Prime Therapeutics in a research report on Thursday, November 7th. Guggenheim started coverage on shares of Five Prime Therapeutics in a research report on Wednesday, November 20th. They set a “hold” rating for the company. Finally, Zacks Investment Research upgraded shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $14.40.

Several institutional investors have recently added to or reduced their stakes in the company. Man Group plc lifted its holdings in shares of Five Prime Therapeutics by 15.2% in the 3rd quarter. Man Group plc now owns 1,336,847 shares of the biotechnology company’s stock worth $5,180,000 after acquiring an additional 176,436 shares during the last quarter. Squarepoint Ops LLC lifted its holdings in shares of Five Prime Therapeutics by 506.9% in the 3rd quarter. Squarepoint Ops LLC now owns 207,823 shares of the biotechnology company’s stock worth $805,000 after acquiring an additional 173,581 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Five Prime Therapeutics by 8.9% in the 3rd quarter. Rhumbline Advisers now owns 57,190 shares of the biotechnology company’s stock worth $222,000 after acquiring an additional 4,657 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Five Prime Therapeutics by 23.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 487,857 shares of the biotechnology company’s stock worth $1,890,000 after acquiring an additional 91,578 shares during the last quarter. Finally, Walleye Trading Advisors LLC bought a new stake in shares of Five Prime Therapeutics in the 2nd quarter worth about $286,000. Hedge funds and other institutional investors own 73.32% of the company’s stock.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.

Further Reading: How are Outstanding Shares Different from Authorized Shares?

Insider Buying and Selling by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

VelocityShares 3x Inverse Crude Oil ETN  Stock Price Down 2.7%
VelocityShares 3x Inverse Crude Oil ETN Stock Price Down 2.7%
Proteon Therapeutics Inc  Short Interest Down 40.6% in November
Proteon Therapeutics Inc Short Interest Down 40.6% in November
Randolph Bancorp Inc  Short Interest Down 25.4% in November
Randolph Bancorp Inc Short Interest Down 25.4% in November
Insider Selling: ITT Inc  Director Sells 2,399 Shares of Stock
Insider Selling: ITT Inc Director Sells 2,399 Shares of Stock
Insider Selling: Mercury Systems Inc  CEO Sells 6,250 Shares of Stock
Insider Selling: Mercury Systems Inc CEO Sells 6,250 Shares of Stock
CBIZ, Inc.  Insider Sells $945,350.00 in Stock
CBIZ, Inc. Insider Sells $945,350.00 in Stock


© 2006-2019 Ticker Report